Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials
Clinical Lymphoma and Myeloma · 2009-12 · 9 (6) · 417-424
DOI: 10.3816/clm.2009.n.083 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Lymphoma and Myeloma, 2009-12. Verfasst von Jirí Pavlů und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Haematology, Hammersmith Hospitals Trust, Imperial College, London W12 0NN, UK. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Haematology, Hammersmith Hospitals Trust, Imperial College, London W12 0NN, UK.
Zitieren
APA
Pavlů, J., & Marin, D. (2009). Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials. Clinical Lymphoma and Myeloma, 9(6), 417-424. https://doi.org/10.3816/clm.2009.n.083
Vancouver
Pavlů J, Marin D. Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials. Clinical Lymphoma and Myeloma. 2009;9(6):417-424. doi:10.3816/clm.2009.n.083
BibTeX
@article{Pavl2009,
author = {Pavlů, Jirí and Marin, David},
title = {Dasatinib and Chronic Myeloid Leukemia: Two-Year Follow-up in Eight Clinical Trials},
journal = {Clinical Lymphoma and Myeloma},
year = {2009},
volume = {9},
number = {6},
pages = {417--424},
doi = {10.3816/clm.2009.n.083}
}
EUVIMED